XNCR Xencor, Inc.

NASDAQ
$23.34

Xencor, Inc. (XNCR) is expected to report earnings on November 4, 2026, after the market close. The consensus earnings estimate is a loss of $0.21 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +6.3% since its last earnings release on August 5, 2026.

Xencor Beat Consensus Estimates
Wednesday, August 5, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 4
Wednesday · 4:00 PM ET
Earnings Whisper
-
vs ($0.21)
Rev est $22.49M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $22.02

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Xencor, Inc.

Xencor Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs.

Sector

Healthcare

Industry

Biotechnology